Kidney Function Tests Market Size
The Kidney Function Tests Market reached US$ 1.12 billion in 2025 and is expected to reach US$ 1.77 billion by 2033, growing with a CAGR of 5.87% during the forecast period 2026-2033.
Kidneys are vital organs in the human body. The kidney filters blood, reabsorbs important components and eliminates soluble waste materials from the blood. They require continual regeneration of dead nephrons and proper blood circulation to support cell proliferation. A kidney function test can diagnose renal diseases such as trouble urinating due to excess bodily fluids, swelling in the hands or feet, and a swollen face.
Kidney Function Tests Market Strategic Insights
| Metrics | Details |
| Market CAGR | 5.87% |
| Segments Covered | By Product Type, By Test Type, By End-User and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Download Sample
Kidney Function Tests Market Companies and Competitive Landscape
Major key players in the kidney function tests market are F. Hoffmann-La Roche Ltd, Nova Biomedical, Quest Diagnostics, 77 Elektronika Kft, ACON Laboratories, Inc., Beckman Coulter, Abbott, bioMérieux SA, OPTI Medical, Siemens Healthineers.
Hoffmann-La Roche Ltd:
Overview:
Hoffmann-La Roche Ltd is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. It is one of the largest biotech companies, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. It is a global leader in in-vitro and tissue-based cancer diagnostics and a frontrunner in diabetes management. Its personalized healthcare strategy aims to provide medicines and diagnostics that enable tangible improvements in patients' health, quality of life and survival. Moreover, Roche Molecular, one of four customer-focused areas of Roche Diagnostics Solutions, develops, manufactures and supplies a wide array of innovative molecular diagnostic products, tests, platforms and technologies used to identify and quantify DNA and RNA from different organisms.
Product Portfolio:
Micral-Test strip: The Micral-Test strip is an easy to use test designed to deliver quick and accurate results, specific for human albumin and sensitive across the diagnostic range.
Recent Developments
- February 2026 – Biomarker innovation improves diagnostic precision
Emerging biomarkers such as cystatin C, NGAL, and KIM-1 are complementing traditional creatinine-based tests, enabling earlier and more accurate detection of kidney dysfunction. - February 2026 – Quest Diagnostics expands renal testing services and population health programs
Quest Diagnostics is strengthening its lab testing networks and chronic disease management programs, supporting large-scale kidney disease screening initiatives. - January 2026 – Growth of home-based and remote kidney monitoring solutions
The market is witnessing increased interest in home testing kits and digital health integration, enabling patients to monitor kidney function outside clinical environments. - January 2026 – Nova Biomedical and Beckman Coulter focus on critical care diagnostics
Companies such as Nova Biomedical and Beckman Coulter are advancing blood gas and electrolyte analyzers, essential for assessing kidney function in ICU settings.
The global kidney function tests market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.
